Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ Form 10-K _________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number: 001-36183 Eiger BioPharmaceuticals, Inc. (Exact Name of Registrant as Specified in its C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number: 001-36183 Eiger BioPharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number: 001-36183 Eiger BioPharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Chart ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ Form 10-K _________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - President and CEO Sri Ryali - Chief Financial Officer Eldon Mayer - Chief Commercial Officer Ingrid Choong - Senior Vice President, Clinical Development Colin Hislop - Senior Vice President, Clinical & Development Operations Colleen Craig - Vice President, Metabolic Diseases Conference Call Participants Maury Ray ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number: 001-36183 | --- | --- | |--------------------------------------------------------------- ...

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingrid Choong - SVP-Clinical Development Eldon Mayer - Chief Commercial Officer Sriram Ryali - CFO Colleen Craig - VP-Metabolic Diseases Conference Call Participants Maurice Raycroft - Jefferies Robert Hazlett - BTIG Michael Higgins - Ladenburg Thalmann Operator [Starts Abruptly] and business update conference call. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number: 001-36183 | --- | --- | |-------------------------------------------------------------------- ...

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs David Cory - President & Chief Executive Officer Ingrid Choong - Senior Vice President-Clinical Development Eldon Mayer - Chief Commercial Officer Sri Ryali - Chief Financial Officer Colleen Craig - Vice President-Metabolic Diseases Conference Call Participants Ashik Mubarack - Citi Bert Hazlett - BTIG Luke Herrmann - Baird Michae ...